Privo Technologies, Inc.
Peabody, MA
- UEI
- E6ACGUBJMQC5
- CAGE
- 629Y5
- SAM.gov registration
- Active through
Company facts
- Self-certified in SAM.gov
- Entity structure
- Corporate Entity (Not Tax Exempt)
- SAM.gov registration date
- Physical address
- 200 Corporate Pl #6b, Peabody, MA 01960, USA
- Website
- privotechnologies.com
- Founded
- 2016
- Employees
- 1-10
- Estimated annual revenue
- $1M-$10M
- Industry
-
- Health Care
- Pharmaceuticals, Biotechnology & Life Sciences
- Pharmaceuticals
- SIC code
- 28 Chemical & Allied Products
Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .
Contract awards
Grant awards
Latest 5 listed here. See the rest on GovTribe.
Similar vendors
About the company
Privo Technologies, Inc. is a biotechnology company specializing in the development of innovative cancer treatment technologies, particularly for oral cancers. The company focuses on creating nanotechnology-based treatments that offer less invasive alternatives to traditional surgical interventions. Privo Technologies has received both federal contract and grant awards from the National Institutes of Health (NIH) and the National Cancer Institute (NCI) to support its research and development efforts. The company is registered with SAM.gov and qualifies as a minority-owned, woman-owned, and economically disadvantaged small business.
Through federal contract awards, Privo Technologies has engaged in research and development under the Small Business Innovation Research (SBIR) program. In September 2022, the company was awarded a $2,049,944 firm fixed price definitive contract by the NIH NCI for a Phase II SBIR project. This contract, set to run until September 2024, focuses on developing PRV311, a standalone, safe, effective, and affordable treatment for early-stage cervical cancer in low- and middle-income countries. The work is being conducted at Privo Technologies' facility in Peabody, Massachusetts, under a total small business set-aside solicitation aimed at advancing public health goals through innovative medical technologies.
Privo Technologies has also received significant federal grant funding to support its research and clinical trials. In June 2024, the company was awarded a $2,084,026 grant from the NCI under the Cancer Treatment Research program to support a Phase 3 clinical trial for PRV111, a topical nanotechnology-based treatment for carcinoma in situ of the oral cavity. This grant, running through May 2027, aims to demonstrate the chemoablative efficacy of PRV111 as an alternative to invasive surgery for early-stage oral cancer patients. Additionally, Privo received a grant in March 2022 to conduct clinical studies for improving survival rates for oral cancer patients in low-resource settings. This project, scheduled to conclude in March 2025, focuses on developing PRV211, a nano-engineered hydrogel designed for intraoperative application to treat locoregional disease and reduce tumor recurrence in oral squamous cell carcinoma patients.
Quick answers
Is Privo Technologies, Inc. registered in SAM.gov?
Yes. Privo Technologies, Inc.'s SAM.gov registration is active through November 30, 2026.
What is Privo Technologies, Inc.'s most recent federal award?
Privo Technologies, Inc.'s most recent federal grant award is Support for registration enabling phase 3 clinical trial for nanotechnology-based treatment of carcinoma in situ of the… (R44CA281020), from National Cancer Institute (NIH), on June 14, 2024.
On GovTribe
See Privo Technologies, Inc.'s full federal record
- Federal contract awards
- Federal grant awards
- Funding analysis by agency, NAICS and set-aside
- Similar vendors